GlassScriptPhysician profile
Edward J Zajac
NPI 1265406060
$27,149.08
in general payments reported to CMS, 2019-2025
24 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,822 · 2021: $378 · 2022: $1,320 · 2023: $391 · 2024: $2,980 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,976 · Food and Beverage: $1,481 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,976.36 |
| Food and Beverage | $1,481.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20,146.29 | 2019-2025 | |
| Medtronic, INC. | $3,635.97 | 2021-2025 | Onyx Frontier, Micra, Ffrangio |
| Boston Scientific Corporation | $1,422.54 | 2019-2025 | General - Therapies, Eluvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.85 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $225.94 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $165.84 | 2020-2024 | Andexxa, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $138.74 | 2019-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $115.31 | 2022 | |
| Abbott Laboratories | $106.28 | 2021-2024 | Gallant |
| Amgen INC. | $103.04 | 2019 | |
| Abiomed | $90.86 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $89.01 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $80.21 | 2022 | |
| Inari Medical, INC. | $80.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $78.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.95 | 2019-2025 | |
| Chiesi USA, INC. | $35.25 | 2022-2023 | Kengreal, Cleviprex |
| Cardiva Medical, INC. | $33.02 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Biotronik INC. | $30.47 | 2020-2021 | |
| Penumbra, INC. | $20.91 | 2023 | Indigo System |
| Terumo Medical Corporation | $15.57 | 2022 | |
| Cardiovascular Systems INC. | $14.51 | 2021 | |
| Merck Sharp & Dohme LLC | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Zajac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.